Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Pfizer weight-loss drug data raises questions about side effects, shares fall

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

Pfizer’s stock falls after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...
Crain's New York Business

Pfizer takes small step toward obesity market, but investors question limited trial results

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...
Medical Marketing & Media

Five things for pharma marketers to know for Wednesday, February 4, 2026

Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?; Trump administration pressed on details of its recent drug price deals; Measles cases identified at ICE’s largest detention facility ...